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Introduction
Antibiotics have transformed the practice of medicine, making 
once lethal infections readily treatable and making other medical 
advances, like cancer chemotherapy and organ transplants, possible. 
The prompt initiation of antibiotics to treat infections has been 
proven to reduce morbidity and save lives, with a recent example 
being the rapid administration of antibiotics in the management of 
sepsis.1 However, 20–50% of all antibiotics prescribed in U.S. acute 
care hospitals are either unnecessary or inappropriate.2–7 Like all 
medications, antibiotics have serious side effects, including adverse 
drug reactions and Clostridium difficile infection (CDI).8–11 Patients 
who are unnecessarily exposed to antibiotics are placed at risk 
for serious adverse events with no clinical benefit. The misuse of 
antibiotics has also contributed to the growing problem of antibiotic 
resistance, which has become one of the most serious and growing 
threats to public health.12 Unlike other medications, the potential for 
spread of resistant organisms means that the misuse of antibiotics 
can adversely impact the health of patients who are not even 
exposed to them. The Centers for Disease Control and Prevention 
(CDC) estimates more than two million people are infected with 
antibiotic-resistant organisms, resulting in approximately 23,000 
deaths annually.13
Improving the use of antibiotics is an important patient safety 
and public health issue as well as a national priority.14 The 2006 
CDC guideline “Management of Multi-Drug Resistant Organisms 
in Healthcare Settings” stated that control of multi-drug resistant 
organisms in healthcare “must include attention to judicious 
antimicrobial use.”15 In 2009, CDC launched the “Get Smart for 
Healthcare Campaign” to promote improved use of antibiotics in 
acute care hospitals and in 2013;16 the CDC highlighted the need 
to improve antibiotic use as one of four key strategies required to 
address the problem of antibiotic resistance in the U.S.13
A growing body of evidence demonstrates that hospital based 
programs dedicated to improving antibiotic use, commonly referred 
to as “Antibiotic Stewardship Programs (ASPs),” can both optimize 
the treatment of infections and reduce adverse events associated 
with antibiotic use.17, 18 These programs help clinicians improve the 
quality of patient care19 and improve patient safety through increased 
infection cure rates, reduced treatment failures, and increased 
frequency of correct prescribing for therapy and prophylaxis.20, 21 
They also significantly reduce hospital rates of CDI22–24 and antibiotic 
resistance.25, 26 Moreover these programs often achieve these benefits 
while saving hospitals money.17, 27–30 In recognition of the urgent need 
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to improve antibiotic use in hospitals and the benefits of antibiotic 
stewardship programs, in 2014 CDC recommended that all acute 
care hospitals implement Antibiotic Stewardship Programs.7
This document summarizes core elements of successful hospital 
Antibiotic Stewardship Programs. It complements existing 
guidelines on ASPs from organizations including the Infectious 
Diseases Society of America in conjunction with the Society for 
Healthcare Epidemiology of America, American Society of Health 
System Pharmacists, and The Joint Commission.6, 31, 32 There is no 
single template for a program to optimize antibiotic prescribing in 
hospitals. The complexity of medical decision making surrounding 
antibiotic use and the variability in the size and types of care 
among U.S. hospitals require flexibility in implementation. However, 
experience demonstrates that antibiotic stewardship programs can 
be implemented effectively in a wide variety of hospitals and that 
success is dependent on defined leadership and a coordinated 
multidisciplinary approach.33–36
Summary of Core Elements of Hospital 
Antibiotic Stewardship Programs
•	 Leadership Commitment: Dedicating necessary human, 
financial and information technology resources.
•	 Accountability: Appointing a single leader responsible for 
program outcomes. Experience with successful programs 
show that a physician leader is effective.
•	 Drug Expertise: Appointing a single pharmacist leader 
responsible for working to improve antibiotic use.
•	 Action: Implementing at least one recommended action, 
such as systemic evaluation of ongoing treatment need after 
a set period of initial treatment (i.e. “antibiotic time out” after 
48 hours).
•	 Tracking: Monitoring antibiotic prescribing and resistance 
patterns.
•	 Reporting: Regular reporting information on antibiotic use 
and resistance to doctors, nurses and relevant staff.
•	 Education: Educating clinicians about resistance and  
optimal prescribing.
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Leadership Commitment 
Leadership support is critical to the success of antibiotic stewardship 
programs and can take a number of forms, including:
•	 Formal statements that the facility supports efforts to improve 
and monitor antibiotic use.
•	 Including stewardship-related duties in job descriptions and 
annual performance reviews.
•	 Ensuring staff from relevant departments are given sufficient 
time to contribute to stewardship activities.
•	 Supporting training and education.
•	 Ensuring participation from the many groups that can support 
stewardship activities.
Financial support greatly augments the capacity and impact of a 
stewardship program and stewardship programs will often pay for 
themselves, both through savings in both antibiotic expenditures and 
indirect costs.17, 27–30
Accountability and Drug Expertise
•	 Stewardship program leader: Identify a single leader who 
will be responsible for program outcomes. Physicians have 
been highly effective in this role.6
•	 Pharmacy leader: Identify a single pharmacy leader who will 
co-lead the program.
Formal training in infectious diseases and/or antibiotic stewardship 
benefits stewardship program leaders.6, 37, 38 Larger facilities 
have achieved success by hiring full time staff to develop and 
manage stewardship programs while smaller facilities report other 
arrangements, including use of part-time, off-site expertise and 
hospitalists.33 Hospitalists can be ideal physician leaders for efforts to 
improve antibiotic use given their increasing presence in inpatient care, 
the frequency with which they use antibiotics and their commitment to 
quality improvement.37, 38 The Pharmacy and Therapeutics committee 
should not be considered the stewardship team within a hospital 
if only performing its traditional duties of managing the formulary 
and monitoring drug-related patient safety, though in some smaller 
facilities the pharmacy and therapeutics committee has expanded its 
role to assess and improve antibiotic use.33–36
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Key Support 
The work of stewardship program leaders is greatly enhanced by the 
support of other key groups in hospitals where they are available. 
•	 Clinicians and department heads. As the prescribers of 
antibiotics, it is vital that clinicians are fully engaged in and 
supportive of efforts to improve antibiotic use in hospitals.
•	 Infection preventionists and hospital epidemiologists 
coordinate facility-wide monitoring and prevention of 
healthcare-associated infections and can readily bring their 
skills to auditing, analyzing and reporting data. They can 
also assist with monitoring and reporting of resistance and 
CDI trends, educating staff on the importance of appropriate 
antibiotic use, and implementing strategies to optimize the 
use of antibiotics.39
•	 Quality improvement staff can also be key partners given 
that optimizing antibiotic use is a medical quality and patient 
safety issue.
•	 Laboratory staff can guide the proper use of tests and the 
flow of results. They can also guide empiric therapy by creating 
and interpreting a facility cumulative antibiotic resistance 
report, known as an antibiogram. Lab and stewardship staff 
can work collaboratively to ensure that lab reports present 
data in a way that supports optimal antibiotic use. For facilities 
that have laboratory services performed offsite, information 
provided should be useful to stewardship efforts and contracts 
should be written to ensure this is the case. 
•	 Information technology staff are critical to integrating 
stewardship protocols into existing workflow. Examples 
include embedding relevant information and protocols at 
the point of care (e.g., immediate access to facility-specific 
guidelines at point of prescribing); implementing clinical 
decision support for antibiotic use; creating prompts for 
action to review antibiotics in key situations and facilitating 
the collection and reporting of antibiotic use data.40–45
•	 Nurses can assure that cultures are performed before starting 
antibiotics. In addition, nurses review medications as part of 
their routine duties and can prompt discussions of antibiotic 
treatment, indication, and duration.46, 47 
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Implement Policies and Interventions 
to Improve Antibiotic Use
Key points 
•	 Implement policies that support optimal antibiotic use.
•	 Utilize specific interventions that can be divided into three 
categories: broad, pharmacy driven and infection and 
syndrome specific.
•	 Avoid implementing too many policies and interventions 
simultaneously; always prioritize interventions based on the 
needs of the hospital as defined by measures of overall use 
and other tracking and reporting metrics.
Policies that support optimal antibiotic use
Implement policies that apply in all situations to support optimal 
antibiotic prescribing, for example:
•	 Document dose, duration, and indication. Specify the dose, 
duration and indication for all courses of antibiotics so they 
are readily identifiable. Making this information accessible 
helps ensure that antibiotics are modified as needed and/or 
discontinued in a timely manner.4, 48, 49
•	 Develop and implement facility specific treatment 
recommendations. Facility-specific treatment 
recommendations, based on national guidelines and local 
susceptibilities and formulary options can optimize antibiotic 
selection and duration, particularly for common indications 
for antibiotic use like community-acquired pneumonia, urinary 
tract infection, intra-abdominal infections, skin and soft tissue 
infections and surgical prophylaxis.
Interventions to improve antibiotic use
Choose interventions based on the needs of the facility as well as the 
availability of resources and content expertise; stewardship programs 
should be careful not to implement too many interventions at once.50 
Many potential interventions are highlighted in the CDC/Institute for 
Healthcare Improvement “Antibiotic Stewardship Driver Diagram 
and Change Package.”51 Assessments of the use of antibiotics as 
mentioned in the “Process Measures” section of this document can 
be a starting point for selecting specific interventions.52
Stewardship interventions are listed in three categories below: broad, 
pharmacy-driven; and infection and syndrome specific.
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Broad interventions
•	 Antibiotic “Time outs.” Antibiotics are often started 
empirically in hospitalized patients while diagnostic information 
is being obtained. However, providers often do not revisit the 
selection of the antibiotic after more clinical and laboratory 
data (including culture results) become available.53–56 An 
antibiotic “time out” prompts a reassessment of the continuing 
need and choice of antibiotics when the clinical picture is 
clearer and more diagnostic information is available. All 
clinicians should perform a review of antibiotics 48 hours after 
antibiotics are initiated to answer these key questions:
Does this patient have an infection that will respond 
to antibiotics?
If so, is the patient on the right antibiotic(s), dose, and 
route of administration?
Can a more targeted antibiotic be used to treat the 
infection (de-escalate)?
How long should the patient receive the antibiotic(s)? 
•	 Prior authorization. Some facilities restrict the use of certain 
antibiotics based on the spectrum of activity, cost, or associated 
toxicities57 to ensure that use is reviewed with an antibiotic 
expert before therapy is initiated. This intervention requires the 
availability of expertise in antibiotic use and infectious diseases 
and authorization needs to be completed in a timely manner. 
•	 Prospective audit and feedback. External reviews of antibiotic 
therapy by an expert in antibiotic use have been highly effective 
in optimizing antibiotics in critically ill patients and in cases 
where broad spectrum or multiple antibiotics are being used.25, 58, 
59 Prospective audit and feedback is different from an antibiotic 
”time out” because the audits are conducted by staff other than 
the treating team. Audit and feedback requires the availability 
of expertise and some smaller facilities have shown success by 
engaging external experts to advise on case reviews.33
Pharmacy-driven Interventions
•	 Automatic changes from intravenous to oral antibiotic 
therapy in appropriate situations and for antibiotics with 
good absorption (e.g., fluoroquinolones, trimethoprim-
sulfamethoxazole, linezolid, etc.),60, 61 which improves patient 
safety by reducing the need for intravenous access.
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•	 Dose adjustments in cases of organ dysfunction (e.g. renal 
adjustment).
•	 Dose optimization including dose adjustments based on 
therapeutic drug monitoring, optimizing therapy for highly 
drug-resistant bacteria, achieving central nervous system 
penetration, extended-infusion administration of beta-
lactams, etc.62, 63
•	 Automatic alerts in situations where therapy might be 
unnecessarily duplicative including simultaneous use of 
multiple agents with overlapping spectra e.g. anaerobic 
activity, atypical activity, Gram-negative activity and resistant 
Gram-positive activity.64
•	 Time-sensitive automatic stop orders for specified 
antibiotic prescriptions, especially antibiotics administered for 
surgical prophylaxis.65
•	 Detection and prevention of antibiotic-related drug-
drug interactions e.g. interactions between some orally 
administered fluoroquinolones and certain vitamins.
Infection and syndrome specific interventions
The interventions below are intended to improve prescribing for 
specific syndromes; however, these should not interfere with prompt 
and effective treatment for severe infection or sepsis.
•	 Community-acquired pneumonia. Interventions for 
community-acquired pneumonia have focused on correcting 
recognized problems in therapy, including: improving 
diagnostic accuracy, tailoring of therapy to culture results and 
optimizing the duration of treatment to ensure compliance 
with guidelines.66–70
•	 Urinary tract infections (UTIs). Many patients who get 
antibiotics for UTIs actually have asymptomatic bacteriuria 
and not infections.71, 72 Interventions for UTIs focus on 
avoiding unnecessary urine cultures and treatment of patients 
who are asymptomatic and ensuring that patients receive 
appropriate therapy based on local susceptibilities and for the 
recommended duration.73–77
•	 Skin and soft tissue infections. Interventions for skin and 
soft tissue infections have focused on ensuring patients do 
not get antibiotics with overly broad spectra and ensuring the 
correct duration of treatment.60, 78, 79
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•	 Empiric coverage of methicillin-resistant Staphylococcus 
aureus (MRSA) infections. In many cases, therapy for 
MRSA can be stopped if the patient does not have an 
MRSA infection or changed to a beta-lactam if the cause is 
methicillin-sensitive Staphylococcus aureus.58, 80
•	 Clostridium difficile infections. Treatment guidelines for CDI 
urge providers to stop unnecessary antibiotics in all patients 
diagnosed with CDI, but this often does not occur.81–84 
Reviewing antibiotics in patients with new diagnoses of CDI 
can identify opportunities to stop unnecessary antibiotics 
which improve the clinical response of CDI to treatment and 
reduces the risk of recurrence.82, 85
•	 Treatment of culture proven invasive infections. 
Invasive infections (e.g. blood stream infections) present 
good opportunities for interventions to improve antibiotic 
use because they are easily identified from microbiology 
results. The culture and susceptibility testing often provides 
information needed to tailor antibiotics or discontinue them 
due to growth of contaminants.86
Tracking and Reporting Antibiotic Use 
and Outcomes
Monitoring antibiotic prescribing
Measurement is critical to identify opportunities for improvement 
and assess the impact of improvement efforts.87 For antibiotic 
stewardship, measurement may involve evaluation of both process 
(Are policies and guidelines being followed as expected?) and 
outcome (Have interventions improved antibiotic use and patient 
outcomes?).
Antibiotic use process measures
Perform periodic assessments of the use of antibiotics or the 
treatment of infections to determine the quality of antibiotic use. 
Examples include determining if prescribers have: accurately applied 
diagnostic criteria for infections; prescribed recommended agents 
for a particular indication; documented the indication and planned 
duration of antibiotic therapy; obtained cultures and relevant tests 
prior to treatment; and modified antibiotic choices appropriately to 
microbiological findings. Standardized tools such as those for drug 
use evaluations or antibiotic audit forms like those developed by 
CDC can assist in these reviews.88 Likewise, assess if antibiotics are 
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being given in a timely manner and assess compliance with hospital 
antibiotic use policies such as the documentation of dose, duration 
and indication or the performance of reassessments of therapy 
(antibiotic time outs). These reviews can be done retrospectively 
on charts which could be identified based on pharmacy records or 
discharge diagnoses. If conducted over time, process reviews assess 
the impact of efforts to improve use. For interventions that provide 
feedback to clinicians, it is also important to document interventions 
and track responses to feedback (e.g., acceptance).
Antibiotic use measures
Measure antibiotic use as either days of therapy (DOT) or defined 
daily dose (DDD). DOT is an aggregate sum of days for which any 
amount of a specific antimicrobial agent is administered or dispensed 
to a particular patient (numerator) divided by a standardized 
denominator (e.g., patient days, days present, or admissions).44, 89 If 
a patient is receiving two antibiotics for 10 days, the DOT numerator 
would be 20. An alternative measure of antibiotic use is defined 
daily dose (DDD). This metric estimates antibiotic use in hospitals by 
aggregating the total number of grams of each antibiotic purchased, 
dispensed, or administered during a period of interest divided by 
the World Health Organization-assigned DDD.90 DDDs are often 
available in facilities with pharmacy systems that cannot calculate 
DOTs. Compared to DOT, DDD estimates are not appropriate for 
children, are problematic for patients with reduced drug excretion 
such as renal impairment, and are less accurate for between-
facility benchmarking.91 However, DDDs can be a useful measure of 
progress when tracked using a consistent methodology over time.92–95 
In addition to measuring overall hospital antibiotic use, antibiotic 
stewardship programs should also focus analyses on specific 
antibiotic(s) and hospital locations where stewardship actions are 
implemented. For example, the assessment of an intervention to 
improve the treatment of community-acquired pneumonia (CAP) 
would be expected to impact the use of antibiotics most commonly 
used to treat CAP on medical wards, rather than surgical wards.
As part of the National Healthcare Safety Network (NHSN), CDC has 
developed an Antibiotic Use (AU) Option that automatically collects 
and reports monthly DOT data, which can be analyzed in aggregate 
and by specific agents and patient care locations. The AU module 
is available to facilities that have information system capability to 
submit electronic medication administration records (eMAR) and/or 
bar coding medication records (BCMA) using an HL7 standardized 
clinical document architecture. To participate in the AU option, 
facility personnel can work with their information technology staff 
and potentially with their pharmacy information software providers to 
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configure their system to enable the generation of standard formatted 
file(s) to be imported into NHSN.44, 89 As more facilities enroll in the AU 
option, CDC will begin to establish risk adjusted facility benchmarks 
for antibiotic use. This type of benchmarking has been helpful in 
improving outcomes in hospital infection control and has been 
identified by stewardship experts as a high priority for the U.S.96
Outcome measures
Track clinical outcomes that measure the impact of interventions 
to improve antibiotic use. Improving antibiotic use has a significant 
impact on rates of hospital onset CDI and the current challenge 
of CDI in hospitals makes this an important target for stewardship 
programs.10, 18, 24, 57 An advantage of this measure is that most acute 
care hospitals are already monitoring and reporting information on 
CDI into NHSN as part of the Centers for Medicare and Medicaid 
Services Hospital Inpatient Quality Reporting Program.
Reducing antibiotic resistance is another important goal of efforts to 
improve antibiotic use and presents another option for measurement. 
The development and spread of antibiotic resistance is multi-
factorial and studies assessing the impact of improved antibiotic 
use on resistance rates have shown mixed results.97–99 The impact 
of stewardship interventions on resistance is best assessed when 
measurement is focused on pathogens that are recovered from 
patients after admission (when patients are under the influence of the 
stewardship interventions). Monitoring resistance at the patient level 
(i.e. what percent of patients develop resistant super-infections) has 
also been shown to be useful.99
Stewardship programs can result in significant annual drug cost 
savings and even larger savings when other costs are included.18, 
20, 21, 100 These savings have been helpful in garnering support for 
antibiotic stewardship programs. If hospitals monitor antibiotic 
costs, consideration should be given to assessing the pace at 
which antibiotic costs were rising before the start of the stewardship 
program.101 After an initial period of marked costs savings, antibiotic 
use patterns and savings often stabilize, so continuous decreases 
in antibiotic use and cost should not be expected; however, it is 
important to continue support for stewardship to maintain gains as 
costs can increase if programs are terminated.30
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Education
Antibiotic stewardship programs should provide regular updates 
on antibiotic prescribing, antibiotic resistance, and infectious 
disease management that address both national and local issues.2 
Sharing facility-specific information on antibiotic use is a tool to 
motivate improved prescribing, particularly if wide variations in the 
patterns of use exist among similar patient care locations.102 There 
are many options for providing education on antibiotic use such as 
didactic presentations which can be done in formal and informal 
settings, messaging through posters and flyers and newsletters or 
electronic communication to staff groups. Reviewing de-identified 
cases with providers where changes in antibiotic therapy could 
have been made is another useful approach. A variety of web-
based educational resources are available that can help facilities 
develop education content.103, 104 Education has been found to be 
most effective when paired with corresponding interventions and 
measurement of outcomes.6
Emerging Developments in Antibiotic 
Stewardship
Strategies for improving antibiotic use and evidence for best 
practices in antibiotic stewardship are evolving. The integration of IT 
into the clinical data presentation and decision-making for antibiotic 
use will expand with increased uptake and capabilities of electronic 
health records. The role of diagnostic laboratory testing is another 
area of evolution. Rapid diagnostic tests such as procalcitonin, 
fluorescence in situ hybridization using peptide nucleic acid probes 
(PNA FISH), and matrix-assisted laser desorption/ionization time 
of flight (MALDI-TOF) mass spectrometric analysis have been 
successfully incorporated by some stewardship programs and may 
become important additions to stewardship efforts.105–108 The use of 
these diagnostic tools on patient care is an area of great interest, and 
further research is needed to determine how they can best be applied 
to stewardship efforts. Another area of on-going work is better 
characterization of the impact of antibiotic stewardship interventions 
on resistance. As more facilities engage in efforts to optimize 
antibiotic use, future work is needed to evaluate which interventions 
or antibiotic targets yield the greatest benefit in combating antibiotic 
resistance. In order to support this work, CDC’s NHSN will launch 
the Antimicrobial Resistance (AR) Option in the summer of 2014 
to facilitate evaluation of antimicrobial resistance data using a 
standardized approach.89
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Checklist for Core Elements of  
Hospital Antibiotic Stewardship Programs
The following checklist is a companion to Core Elements of Hospital Antibiotic Stewardship Programs. 
This checklist should be used to systematically assess key elements and actions to ensure optimal 
antibiotic prescribing and limit overuse and misuse of antibiotics in hospitals. CDC recommends that 
all hospitals implement an Antibiotic Stewardship Program.
Facilities using this checklist should involve one or more knowledgeable staff to determine if the 
following principles and actions to improve antibiotic use are in place. The elements in this checklist 
have been shown in previous studies to be helpful in improving antibiotic use though not all of the 




A. Does your facility have a formal, written statement of support from leadership that supports 
efforts to improve antibiotic use (antibiotic stewardship)?
❑ Yes ❑ No
B. Does your facility receive any budgeted financial support for antibiotic stewardship activities 
(e.g., support for salary, training, or IT support)?
❑ Yes ❑ No
ACCOUNTABILITY
A. Is there a physician leader responsible for program outcomes of stewardship activities at your 
facility?
❑ Yes ❑ No
DRUG EXPERTISE
A. Is there a pharmacist leader responsible for working to improve antibiotic use at your facility? ❑ Yes ❑ No
KEY SUPPORT FOR THE ANTIBIOTIC STEWARDSHIP PROGRAM
Does any of the staff below work with the stewardship leaders to improve antibiotic use?
B. Clinicians ❑ Yes ❑ No
C. Infection Prevention and Healthcare Epidemiology ❑ Yes ❑ No
D. Quality Improvement ❑ Yes ❑ No
E. Microbiology (Laboratory) ❑ Yes ❑ No
F. Information Technology (IT) ❑ Yes ❑ No
G. Nursing ❑ Yes ❑ No
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A. Does your facility have a policy that requires prescribers to document in the medical record or 
during order entry a dose, duration, and indication for all antibiotic prescriptions?
❑ Yes ❑ No
B. Does your facility have facility-specific treatment recommendations, based on national guidelines 
and local susceptibility, to assist with antibiotic selection for common clinical conditions?
❑ Yes ❑ No
SPECIFIC INTERVENTIONS TO IMPROVE ANTIBIOTIC USE




C. Is there a formal procedure for all clinicians to review the appropriateness of all antibiotics 48 
hours after the initial orders (e.g. antibiotic time out)?
❑ Yes ❑ No
D. Do specified antibiotic agents need to be approved by a physician or pharmacist prior to 
dispensing (i.e., pre-authorization) at your facility?
❑ Yes ❑ No
E. Does a physician or pharmacist review courses of therapy for specified antibiotic agents (i.e., 
prospective audit with feedback) at your facility?
❑ Yes ❑ No
PHARMACY-DRIVEN INTERVENTIONS
Are the following actions implemented in your facility?
ACTION 
PERFORMED
F. Automatic changes from intravenous to oral antibiotic therapy in appropriate situations? ❑ Yes ❑ No
G. Dose adjustments in cases of organ dysfunction? ❑ Yes ❑ No
H. Dose optimization (pharmacokinetics/pharmacodynamics) to optimize the treatment of 
organisms with reduced susceptibility?
❑ Yes ❑ No
I. Automatic alerts in situations where therapy might be unnecessarily duplicative? ❑ Yes ❑ No
J. Time-sensitive automatic stop orders for specified antibiotic prescriptions? ❑ Yes ❑ No
DIAGNOSIS AND INFECTIONS SPECIFIC INTERVENTIONS
Does your facility have specific interventions in place to ensure optimal use of 
antibiotics to treat the following common infections?
ACTION 
PERFORMED
K. Community-acquired pneumonia ❑ Yes ❑ No
L. Urinary tract infection ❑ Yes ❑ No
M. Skin and soft tissue infections ❑ Yes ❑ No
N. Surgical prophylaxis ❑ Yes ❑ No
O. Empiric treatment of Methicillin-resistant Staphylococcus aureus (MRSA) ❑ Yes ❑ No
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A. Non-C. Difficile infection (CDI) antibiotics in new cases of CDI ❑ Yes ❑ No
B. Culture-proven invasive (e.g., blood stream) infections ❑ Yes ❑ No




A. Does your stewardship program monitor adherence to a documentation policy (dose, duration, 
and indication)?
❑ Yes ❑ No
B. Does your stewardship program monitor adherence to facility-specific treatment 
recommendations?
❑ Yes ❑ No
C. Does your stewardship program monitor compliance with one of more of the specific 
interventions in place?
❑ Yes ❑ No
ANTIBIOTIC USE AND OUTCOME MEASURES
MEASURE 
PERFORMED
D. Does your facility track rates of C. difficile infection? ❑ Yes ❑ No
E. Does your facility produce an antibiogram (cumulative antibiotic susceptibility report? ❑ Yes ❑ No
Does your facility monitor antibiotic use (consumption) at the unit and/or facility wide 
level by one of the following metrics:
MEASURE 
PERFORMED
F. By counts of antibiotic(s) administered to patients per day (Days of Therapy; DOT)? ❑ Yes ❑ No
G. By number of grams of antibiotics used (Defined Daily Dose, DDD)? ❑ Yes ❑ No
H. By direct expenditure for antibiotics (purchasing costs)? ❑ Yes ❑ No
REPORTING INFORMATION TO STAFF ON IMPROVING ANTIBIOTIC USE AND RESISTANCE
A. Does you stewardship program share facility-specific reports on antibiotic use with prescribers? ❑ Yes ❑ No
B. Has a current antibiogram been distributed to prescribers at your facility? ❑ Yes ❑ No
C. Do prescribers ever receive direct, personalized communication about how they can improve 
their antibiotic prescribing?
❑ Yes ❑ No
EDUCATION
A. Does your stewardship program provide education to clinicians and other relevant staff on 
improving antibiotic prescribing?
❑ Yes ❑ No
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